Heterozygosity for hypoxia inducible factor 1alpha decreases the incidence of thymic lymphomas in a p53 mutant mouse model.

Hypoxia inducible factors (HIF) are critical mediators of the cellular response to decreased oxygen tension and are overexpressed in a number of tumors. Although HIF1alpha and HIF2alpha share a high degree of sequence homology, recent work has shown that the two alpha subunits can have contrasting and tissue-specific effects on tumor growth. To directly compare the role of each HIFalpha subunit in spontaneous tumorigenesis, we bred a mouse model of expanded HIF2alpha expression and Hif1alpha(+/-) mice to homozygotes for the R270H mutation in p53. Here, we report that p53(R270H/R270H) mice, which have not been previously described, develop a unique tumor spectrum relative to p53(R270H/-) mice, including a high incidence of thymic lymphomas. Heterozygosity for Hif1alpha significantly reduced the incidence of thymic lymphomas observed in this model. Moreover, reduced Hif1alpha levels correlated with decreased stabilization of activated Notch1 and expression of the Notch target genes, Dtx1 and Nrarp. These observations uncover a novel role for HIF1alpha in Notch pathway activation during T-cell lymphomagenesis.

[1]  A. Harris,et al.  The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages , 2000 .

[2]  U. Lendahl,et al.  Constitutive activation of NF‐κB and T‐cell leukemia/lymphoma in Notch3 transgenic mice , 2000, The EMBO journal.

[3]  T. Jacks,et al.  The differential effects of mutant p53 alleles on advanced murine lung cancer. , 2005, Cancer research.

[4]  Kai-Uwe Eckardt,et al.  The FASEB Journal express article 10.1096/fj.02-0445fje. Published online December 17, 2002. Widespread, hypoxia-inducible expression of HIF-2α in distinct cell populations of different organs , 2022 .

[5]  S. McKnight,et al.  Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. , 1997, Genes & development.

[6]  F. Alt,et al.  Histone H2AX A Dosage-Dependent Suppressor of Oncogenic Translocations and Tumors , 2003, Cell.

[7]  F. Alt,et al.  Activating Notch1 mutations in mouse models of T-ALL. , 2005, Blood.

[8]  Jonathan Pevsner,et al.  HIF-dependent antitumorigenic effect of antioxidants in vivo. , 2007, Cancer cell.

[9]  Brian Keith,et al.  Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation , 2003, Molecular and Cellular Biology.

[10]  M. Simon,et al.  Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. , 2005, Cancer research.

[11]  T. Jacks,et al.  V(D)J recombination is not required for the development of lymphoma in p53-deficient mice. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[12]  Chi V. Dang,et al.  The interplay between MYC and HIF in cancer , 2008, Nature Reviews Cancer.

[13]  S. Jain,et al.  Expression of ARNT, ARNT2, HIF1 alpha, HIF2 alpha and Ah receptor mRNAs in the developing mouse. , 1998, Mechanisms of development.

[14]  Patrick H. Maxwell,et al.  Contrasting Properties of Hypoxia-Inducible Factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-Associated Renal Cell Carcinoma , 2005, Molecular and Cellular Biology.

[15]  T. Jacks,et al.  Mice expressing a mammary gland-specific R270H mutation in the p53 tumor suppressor gene mimic human breast cancer development. , 2005, Cancer research.

[16]  T. Jacks,et al.  The role of p53 in tumour suppression: lessons from mouse models , 1999, Cellular and Molecular Life Sciences CMLS.

[17]  C. Manetopoulos,et al.  The Notch pathway in cancer: differentiation gone awry. , 2005, European journal of cancer.

[18]  W. Kaelin,et al.  Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth , 2003, PLoS biology.

[19]  M. Hollstein,et al.  p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM , 2007, Nature Cell Biology.

[20]  J. Aster,et al.  Notch signaling in leukemia. , 2001, Current opinion in hematology.

[21]  T. Jacks,et al.  Dominant-negative but not gain-of-function effects of a p53.R270H mutation in mouse epithelium tissue after DNA damage. , 2007, Cancer research.

[22]  Mirna Lechpammer,et al.  Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. , 2002, Cancer cell.

[23]  R. Johnson,et al.  Hypoxia-inducible factor-1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. , 2007, Cancer research.

[24]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.

[25]  A. Harris,et al.  The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. , 2000, The American journal of pathology.

[26]  M. Bhasin,et al.  Notch1 Contributes to Mouse T-Cell Leukemia by Directly Inducing the Expression of c-myc , 2006, Molecular and Cellular Biology.

[27]  T. Ried,et al.  53BP1 Cooperates with p53 and Functions as a Haploinsufficient Tumor Suppressor in Mice , 2005, Molecular and Cellular Biology.

[28]  Brian Keith,et al.  HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. , 2006, Genes & development.

[29]  U. Lendahl,et al.  Hypoxia requires notch signaling to maintain the undifferentiated cell state. , 2005, Developmental cell.

[30]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[31]  J. Sklar,et al.  Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles , 1996, The Journal of experimental medicine.

[32]  Å. Borg,et al.  Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. , 2006, Cancer cell.

[33]  P. Carmeliet,et al.  Genetic evidence for a tumor suppressor role of HIF-2alpha. , 2005, Cancer cell.

[34]  Richard D Klausner,et al.  The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. , 2002, Cancer cell.

[35]  Jon C. Aster,et al.  Essential Roles for Ankyrin Repeat and Transactivation Domains in Induction of T-Cell Leukemia by Notch1 , 2000, Molecular and Cellular Biology.

[36]  R. Johnson,et al.  Acute postnatal ablation of Hif-2alpha results in anemia. , 2007, Proceedings of the National Academy of Sciences of the United States of America.

[37]  T. Iwakuma,et al.  The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. , 2008, Genes & development.

[38]  R. Johnson,et al.  Hypoxia-Inducible Factor-1α Is a Key Regulator of Metastasis in a Transgenic Model of Cancer Initiation and Progression , 2007 .

[39]  G. Camenisch,et al.  Integration of Oxygen Signaling at the Consensus HRE , 2005, Science's STKE.

[40]  Brian Keith,et al.  Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. , 2003, Molecular and cellular biology.

[41]  J. M. Arbeit,et al.  Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth. , 2000, Cancer research.

[42]  M. Simon,et al.  Hypoxia-inducible factors: central regulators of the tumor phenotype. , 2007, Current opinion in genetics & development.

[43]  John D Gordan,et al.  HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. , 2007, Cancer cell.